Navigation Links
Early Esophageal Cancer and Pre-Cancer Eliminated With Non-Surgical Treatment Combination
Date:5/20/2008

Endoscopic ablative therapy with HALO device leads to 100% patient response

rate

SUNNYVALE, Calif., May 20 /PRNewswire/ -- BARRX Medical, Inc., a global technology leader in treating Barrett's esophagus, today announced the publication of two related European trials which report a 100% eradication rate for early esophageal cancer and pre-cancerous dysplasia using endoscopic resection followed by ablation therapy with the HALO ablation system. Barrett's esophagus is a complication of gastroesophageal reflux disease (GERD) and is a known risk factor for esophageal cancer, the fastest growing cancer in the Western world.

Results of the two studies were published in the May issue of Endoscopy, a medical journal for gastroenterologists performing advanced endoscopic procedures. They were titled "Effective treatment of early Barrett's neoplasia with stepwise circumferential and focal ablation using the HALO system," and "Stepwise circumferential and focal ablation of Barrett's esophagus with high- grade dysplasia: results of the first prospective series of 11 patients." The investigators enrolled patients with Barrett's esophagus having early cancer and/or advanced dysplasia, used endoscopic resection to remove focal abnormal areas, then used endoscopic ablative therapy with the HALO system to eradicate all remaining diseased tissue. At one and two year follow-up, respectively, in each trial, all patients were cured of their esophageal disease.

"This data confirms that early cancer and advanced dysplasia can be safely and effectively treated with this non-surgical approach using endoscopic resection and ablation," said Amsterdam Medical Centre (AMC) gastroenterologist and Professor of Medicine Jacques Bergman, M.D., who led the study in Amsterdam, the Netherlands. "We're confident this treatment can reduce the need for high risk surgical procedures and become the preferred strategy for treating patients with Ba
'/>"/>

SOURCE BARRX Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Saving Lives of California Residents Who Develop Skin Cancer Each Year: The Key is Early Detection and Treatment
3. Saving Lives of Florida Residents Who Develop Skin Cancer Each Year: The Key is Early Detection and Treatment
4. First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival
5. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
6. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
7. Neupro(R) (Rotigotine Transdermal System) Effective in Controlling Early Morning Motor Impairment and Generally Well-Tolerated for Long-Term Use in Patients with Parkinsons Disease
8. deCODE Launches deCODE MI(TM) -- A Test for a Major Genetic Risk Factor for Early-onset Heart Attack
9. Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response
10. Study Protocols Will be Amended in Two Small Early-Phase Prasugrel Studies
11. Potential Early Warning System for Lung Cancer Identified
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015  Alimera Sciences, Inc. (NASDAQ: ... the research, development and commercialization of prescription ophthalmic pharmaceuticals, ... fiscal year 2015 financial results after the market close ... will follow on the same day at 4:30 p.m. ... and Chief Executive Officer, and Rick Eiswirth , ...
(Date:7/30/2015)... 2015 EnteroMedics Inc. (NASDAQ: ETRM ), ... treat obesity, metabolic diseases and other gastrointestinal disorders, today ... Thursday, August 6, 2015, at 11:00 AM Eastern Time ... June 30, 2015, and to provide an update on ... via the Maestro® System. Conference Call Details ...
(Date:7/30/2015)... 2015 Tissue Regenix Group ... medical devices company, announces that it has further ... market as Tissue Regenix Wound Care Inc. has ... First Coast Service Options Inc. ("First Coast") whose ... Puerto Rico and the US ...
Breaking Medicine Technology:Alimera Sciences To Release Second Quarter Fiscal Year 2015 Financial Results 2EnteroMedics to Host Second Quarter 2015 Financial Results and Company Update Conference Call 2EnteroMedics to Host Second Quarter 2015 Financial Results and Company Update Conference Call 3Tissue Regenix Group plc: First Coast Service Options Inc. Approves Medicare Coverage for DermaPure 2Tissue Regenix Group plc: First Coast Service Options Inc. Approves Medicare Coverage for DermaPure 3
... , , , , , , ... MIVI-TRUST Phase III Program With Microplasmin Recruits a Total of Over,640 ... (Euronext Brussels: THR), a biopharmaceutical company,focused on the discovery and development ... that it has completed,the enrolment of the second Phase III trial ...
... , NORCROSS, Ga., Dec. 15 Immucor, Inc. (Nasdaq: ... to the blood transfusion industry, today announced that it will ... 6, 2010 after the market close. The Company will host ... a.m. (Eastern Time) to discuss the results. , ...
Cached Medicine Technology:ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease 2ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease 3ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease 4
(Date:7/30/2015)... ... July 30, 2015 , ... ... at the annual All-Stars Summit. Google Partners is the platform for search marketing ... the full support and tools necessary to run successful search marketing campaigns. Google ...
(Date:7/30/2015)... ... , ... Quintessa Medical Spa is happy to offer patients the latest treatment ... for the elimination of excess tissue under the chin, referred to as submental fat. ... to offer this innovative treatment. , Developed by Kythera Biopharmaceuticals, Kybella was approved by ...
(Date:7/30/2015)... ... July 30, 2015 , ... The American ... Chuck Rosenberg’s announcement of the reinstitution of National Prescription Drug Take-Back Days. The ... from 10:00 AM to 2:00 PM local time. On the 26th, the DEA, ...
(Date:7/30/2015)... Raleigh, NC (PRWEB) , ... July 30, 2015 , ... ... older patients. Click here to read more on the Surviving Mesothelioma website. ... Orthopedic Rehabilitation Hospital in Missouri reviewed more than 12,000 cases of mesothelioma occurring between ...
(Date:7/30/2015)... ... 30, 2015 , ... 1Heart Caregiver Services LLC is offering its 1st Business ... in the Booming Homecare Business.” This will be held in its main headquarters at ... event will be hosted by 1Heart’s very own Randy Clarito (Director of Business and ...
Breaking Medicine News(10 mins):Health News:Boston Web Marketing Attends Google Partners All-Stars Summit 2Health News:Quintessa MedSpa Offers Nonsurgical Double-chin Elimination 2Health News:AAPCC Supports National Prescription Drug Take-Back Day 2Health News:AAPCC Supports National Prescription Drug Take-Back Day 3Health News:Study Finds Mesothelioma Behaves Differently in Younger People, According to Surviving Mesothelioma 2Health News:Upcoming Business Seminar at 1Heart Caregiver Services Headquarters Los Angeles California 2
... overeating, slothful horse leads to an obese horse. Unlike humans, ... obese horse. Caretakers may see no harm in giving their ... unhealthy as obesity in humans and can lead to fatal ... humans and horses when it comes to obesity," said Philip ...
... All India Institute of Medical Sciences (AIIMS) has developed ... cancer, underdeveloped genitals.// ,Doctors at the premier ... suffering from such problems, achieving 100 percent success. ... over 50 patients with not a single case of ...
... Divers scouring the sea-bed for abalone are paying with their ... while pursuing abalone, which is used in sushi// and a ... dollars apiece on the black market. ,Abalone are ... this mollusk is considered a delicacy in certain parts of ...
... Gulping down several litres of water to keep oneself cool ... won’t make much difference, warns scientists for marathon runners//. ... average runner will potentially lose almost a litre of sweat ... degrees, two degrees above normal. The sporting community has long ...
... called levodopa or L-dopa that helps in reviving cellular ... may experience motor complications and a reduced response to ... process of destruction of brain cells which produce dopamine. ... up as tremors in the arms, legs and face. ...
... and the possible reasons for them, a survey was ... revealed that present statistics of stillborns remained unchanged upon ... one in 200 pregnancies resulted in stillbirth, the survey ... Health (CEMACH) revealed that there were 3,600 ...
Cached Medicine News:Health News:Humans Aren't the Only Ones With Obesity Problems 2Health News:Artificial Testis Developed by AIIMS a Boon to Suffering Patients 2Health News:Hunt for Sea Delicacy Taking a Toll in California 2Health News:Hunt for Sea Delicacy Taking a Toll in California 3Health News:Large Fluid Intake Won’t Help to Keep Cool for Marathon Runner 2Health News:Stillbirth Figures Stand Still 2
Straight shafts with 1 x 2 teeth. Flat handle with haoles and polished finish. Delicate teeth. Most popular size or model....
Straight shafts with 0.12 mm teeth and 5 mm tying platform. Serrated handle with polished finish. Manufactured in titanium....
Straight shafts with polished finish. Teeth: 0.12 mm. Tying platform: 5.0 mm. Wide Serrated....
Straight shafts with 1 x 2 teeth and 5 mm tying platform. Serrated handle with dull finish....
Medicine Products: